{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-021927","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.102734+00:00","generated_at":"2026-06-12T10:51:29.071035+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OPKO reports Q2 2023 net loss of $19.6M; receives $90M milestone from Pfizer for NGENLA approval","bullets":["Consolidated revenue $265.4M, down from $309.9M YoY; operating income $7.0M vs loss of $10.7M.","Pharma segment revenue rose to $43.5M; $94.9M IP transfer revenue included $90M NGENLA milestone.","Diagnostics revenue fell to $127.0M from $186.8M due to lower COVID-19 testing volume and reimbursement.","Cash and equivalents $108.1M, excluding the $90M milestone payment expected in August 2023.","NGENLA approved in 44 markets; profit sharing with Pfizer begins from August 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-021927","json":"https://secwatch.observer/filing/0001437749-23-021927.json","markdown":"https://secwatch.observer/filing/0001437749-23-021927.md","text":"https://secwatch.observer/filing/0001437749-23-021927.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000143774923021927/0001437749-23-021927-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000143774923021927/opk20230712_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T10:51:29.071035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80f2f7cd63799bd929d5ab25c9cbb70d74d9312a","claim":"OPKO HEALTH, INC. reported the quarter ended June 30, 2023 results: revenue $265.4 million, net income $19.6 million, or $0.03 per share, EPS $0.03 per share.","evidence_excerpt":"BioReference continues to implement cost-reduction initiatives as it works toward profitability. ● Consolidated: Consolidated total revenues for the second quarter of 2023 were $265.4 million compared with $309.9 million for the comparable period of 2022. Operating income for the second quarter of 2023 was $7.0 million compared with an operating loss of $10.7 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/944809/000143774923021927/0001437749-23-021927-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$265.4 million"},{"label":"Net income","value":"$19.6 million, or $0.03 per share"},{"label":"EPS","value":"$0.03 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}